Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 4/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387696 | 0.92 | CTSL (0.64) | C5AR1CTSLCTSSCTSKMC4R | |
| SCHEMBL29655695 | 0.90 | F2 (0.51) | F2OPRM1OPRD1 | |
| SCHEMBL29513768 | 0.89 | CTSL (0.62) | C5AR1CTSLCTSSCTSKMC4R | |
| SCHEMBL29677323 | 0.89 | CTSL (0.67) | C5AR1CTSLCTSSCTSKMC4R | |
| SCHEMBL30821694 | 0.88 | CTSL (0.69) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30974024 | 0.86 | APLNR (0.52) | C5AR1CTSLCTSSCTSKMC4R | |
| SCHEMBL30512520 | 0.86 | F2 (0.61) | C5AR1MC4RAPLNRF2NMUR2 | |
| SCHEMBL31598487 | 0.86 | OPRM1 (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31598478 | 0.86 | OPRM1 (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31437160 | 0.86 | CTSL (0.56) | C5AR1CTSLCTSSCTSKMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673154-A1 | CELL THERAPY FOR TREATING SYSTEMIC AUTOIMMUNE DISEASES | Juno Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182516-A1 | CELL THERAPY FOR TREATING SYSTEMIC AUTOIMMUNE DISEASES | JUNO THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-116802203-A | Cells expressing chimeric receptors from modified constant CD3 immunoglobulin superfamily chain loci, related polynucleotides and methods | 朱诺治疗学股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-109071616-B | Streptavidin muteins and methods of use thereof | IBA股份有限公司 | 2023-09-19 | — | — | CN | disclosed |